PLAINSBORO, N.J., Aug 20, 2008 (GlobeNewswire via COMTEX News Network) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced today that Radionics(R) XKnife(R) clinicians presented their latest advances in the treatment of brain and spine tumors on Sunday, July 27th at the 50th annual meeting of the American Association of Physicists in Medicine in Houston, Texas. The Radionics(R) XKnife(R) radiosurgery system is developed, manufactured, and marketed by Integra LifeSciences Holdings Corporation, through its Integra NeuroSciences team.

Dr. Satish Jaywant, Associate Professor of Radiation Oncology at Robert Wood Johnson University Hospital in New Brunswick, New Jersey, presented his latest work using Radionics(R) XKnife(R) and ImageFusion(TM) software and cone beam CT to achieve stereotactic accuracy for extracranial targets.

Dr. Nilendu Gupta, Associate Professor and Chief of Clinical Medical Physics at James Cancer Center at the Ohio State Medical Center in Columbus, Ohio, presented his work in commissioning the XKnife(R) system for stereotactic spine treatments.

Emilie Soisson, medical physicist and assistant researcher at the University of Wisconsin Hospital and Clinics, presented her work on the Radionics(R) InterFix(TM) system for intracranial stereotactic positioning for use on the TomoTherapy(R) Hi - Art(R) system.

"It's exciting to see the advances our customers are making to treat tumors throughout the body utilizing the Radionics(R) XKnife(R) system as well as the Radionics(R) InterFix(TM) Radiosurgery Kit," said Jason D. Ellnor, Director of Marketing for stereotaxy at Integra NeuroSciences.

Unlike conventional surgery, XKnife(R) radiosurgery is completely noninvasive and does not require a surgical incision. This eliminates the discomfort and complications associated with standard surgery. Cancerous or other diseased tissue can be treated with focused radiation beams from a linear accelerator (linac) that are precisely guided using computer tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) images. Surrounding normal tissue is spared and patients are typically able to leave the hospital immediately after their treatment. To date, over 45,000 patients have undergone Radionics(R) XKnife(R) radiosurgery.

The Radionics(R) InterFix(TM) Radiosurgery Kit provides a way to adapt the existing Integra NeuroSciences stereotactic hardware to the TomoTherapy(R) Hi - Art(R) system for stereotactic treatment of cranial tumors and vascular malformations.

TomoTherapy Incorporated (Nasdaq:TOMO) develops, manufactures and sells the TomoTherapy(R) Hi - Art(R) treatment system, an advanced radiation therapy system for the treatment of a wide variety of cancers. The Hi . Art(R) treatment system combines integrated CT imaging with helical intensity modulated radiation therapy to deliver sophisticated treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. www.tomotherapy.com

Integra NeuroSciences products are currently sold in the United States through the Integra NeuroSciences sales organization. Integra NeuroSciences is a leading provider of implants, devices, instruments, and systems used in neurosurgery. Integra Neurosciences' direct selling effort in North America and Europe currently involves more than 150 professionals. In other markets, Integra NeuroSciences products are sold through a network of distributors.

Integra LifeSciences Holdings Corporation, a world leader in regenerative medicine, is dedicated to improving the quality of life for patients through the development, manufacturing, and marketing of cost-effective surgical implants and medical instruments. The company's products are used to treat millions of patients every year, primarily in neurosurgery, extremity reconstruction, orthopedics and general surgery. Integra's headquarters are in Plainsboro, New Jersey, and it has research and manufacturing facilities throughout the world. www.Integra-LS.com

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the future use of the Radionics(R) XKnife(R), Radionics(R) InterFix(TM) Radiosurgery Kit, and the TomoTherapy(R) Hi - Art(R) system. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of physicians to use these products may affect the prospects for their use in clinical procedures. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in section IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2007 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.

IART - P

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Integra LifeSciences Holdings Corp.

Integra LifeSciences Holdings Corporation
          John B. Henneman, III, Executive Vice President, Finance 
           and Administration, and Chief Financial Officer
            (609) 936-2481
            jhenneman@Integra-LS.com
          Gianna Sabella, Public Relations Manager
            (609) 936-2389
            gsabella@intergra-LS.com

(C) Copyright 2008 GlobeNewswire, Inc. All rights reserved.

News Provided by COMTEX